Truist Securities Maintains Buy on Edwards Lifesciences, Raises Price Target to $84
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst Richard Newitter has reaffirmed a Buy rating on Edwards Lifesciences (NYSE:EW) and increased the price target from $78 to $84. This adjustment reflects a positive outlook on the company's stock.
December 22, 2023 | 2:45 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Truist Securities analyst Richard Newitter maintains a Buy rating on Edwards Lifesciences and raises the price target from $78 to $84, indicating a bullish outlook on the stock.
The increase in price target by Truist Securities suggests that the analyst sees potential for the stock to perform well in the short term. A Buy rating combined with a raised price target typically signals analyst confidence in the company's future performance and can positively influence investor sentiment.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100